[Translation] A multicenter, randomized, single-blind, alteplase (Aitongli) positive-controlled phase III clinical trial of recombinant human urokinase in the treatment of acute ST-segment elevation myocardial infarction
在Ⅰ期、Ⅱ期临床研究的基础上,以rt-PA为阳性对照药,进一步评价对于体重≤85KG的患者,用苏州兰鼎生物制药有限公司研制的重组人尿激酶原600万IU/例静脉溶栓治疗急性ST段抬高型心肌梗死的有效性、安全性。
[Translation] On the basis of Phase I and Phase II clinical studies, rt-PA was used as a positive control drug to further evaluate the effectiveness and safety of intravenous thrombolysis for the treatment of acute ST-segment elevation myocardial infarction in patients with body weight ≤ 85KG using 6 million IU/case of recombinant human urokinase developed by Suzhou Landing Biopharmaceuticals Co., Ltd.